@article{10.37349/emd.2024.00074,
abstract = {Obesity is widely recognized as being associated with both the onset and advancement of gout, exerting a detrimental effect on health outcomes in society. In the realm of gout management, theoretical frameworks support weight loss as a beneficial strategy for people impacted by overweight or obesity. Existing empirical evidence is limited to a handful of predominantly observational studies with low methodological rigor A recent exploratory clinical trial which included 61 people with obesity and gout randomly allocated participants to either an intensive diet group (n = 29) or a control diet group (n = 32). After 16 weeks, a significant difference in body weight change was observed between the intensive diet group and the control diet group [−7.7 kg (95% confidence interval −10.7 to −4.7)]. Although the results leaned towards favoring a low-energy diet, differences in changes in serum urate (SU) levels and fatigue between the groups could not be confirmed. For the majority of individuals who lose weight a key challenge is long term maintenance. Novel agents such as glucagon-like peptide-1 receptor agonists (GLP-1Ras) have a role in weight loss and its maintenance. In this manuscript we propose what we consider the ideal target trial for weight loss in gout. We envision a two-year randomized trial with participants allocated to either a GLP-1RA or placebo and evaluated and monitored over a two-year period.},
author = {Christensen, Robin and Haugegaard, Tobias and Morillon, Melanie B. and Gudbergsen, Henrik and Bliddal, Henning and Stamp, Lisa K.},
doi = {10.37349/emd.2024.00074},
journal = {Exploration of Musculoskeletal Diseases},
pages = {498--508},
title = {{Addressing weight loss management in obese gout patients: guidance for future trials}},
url = {https://doi.org/10.37349/emd.2024.00074},
volume = {2},
year = {2024},
number = {6}
}